GeNeuro

Researchers Detect HERV-W ENV in COVID-19 Patients and Link Expression to Disease Severity - Seite 3

“GeNeuro is focused on developing treatments to neutralize the pathogenic effects of HERVs for the benefit of patients. Our main focus is on autoimmune and neurodegenerative diseases, such as MS, where the link between HERVs and disease is best established,” said Jesús Martin-Garcia, CEO of GeNeuro. “We are intrigued by these very novel findings, which show once again the importance of HERV biology to understand and tackle severe conditions. As the leaders in the HERV field and with HERV-W ENV as a possible aggravating agent of COVID-19, we have started working with leading medical centers in Europe and the USA to evaluate temelimab as a therapeutic treatment, both to prevent immune system hyper-activation in recently infected patients, as well as to tackle severe neurological and psychiatric syndromes in long-COVID patients. Without any prejudice to our existing programs, we have enough temelimab to start both tracks of clinical trials, as early as this summer.”

About GeNeuro

GeNeuro‘s mission is to leverage HERV biology to develop safe and effective treatments for the benefit of patients, by neutralizing causal factors encoded by HERVs that represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.

For more information, visit: www.geneuro.com

About University of Rome “Tor Vergata”

The University of Rome “Tor Vergata” was established in 1982. Designed on the model of Anglo-Saxon campuses, it hosts important research institutions, such as the National Research Council – CNR and the Italian Space Agency – ASI. Tor Vergata’s School of Medicine and Surgery is ranked among the top academic medical centers in Italy and its Department of Experimental Medicine works closely with the “Policlinic Tor Vergata” university hospital. For more information, visit https://en.uniroma2.it/.

About the International Center for Infectiology Research (CIRI)

The International Center for Infectiology Research (CIRI) is a joint research unit of the Lyon 1 University, Inserm, CNRS and the ENS de Lyon in partnership with VetAgro Sup, the Institut Pasteur and the Hospices Civils de Lyon. The CIRI gathers the scientific and medical research communities with complementary disciplinary backgrounds grouped in 3 specialties working together with the objective to understand host-microbe interactions to better fight infectious diseases. For more information, visit https://ciri.ens-lyon.fr